Abstract: The invention relates to direct-fed microbials for use in E. coli inhibition in animals. More particularly, the invention relates to isolated Bacillus strains 101, 235, 77, 177, and 102 and strains having all of the identifying characteristics of these strains, for a use comprising the above-mentioned use. The invention can also be used for treatment of plants and in food processing.

Abstract: The invention relates to microbials for use in improving the health of a human and animals. More particularly, the invention relates to isolated Bacillus strains, and strains having all of the identifying characteristics of these strains, for a use comprising the above-mentioned use, in particular for improving the gastrointestinal health of animals or humans.

Abstract: The invention relates to direct-fed microbials for use in E. coli, Salmonella, and/or Campylobacter inhibition in animals. More particularly, the invention relates to isolated Bacillus strains A12, 54, 681, 101, 235, and 721, and strains having all of the identifying characteristics of these strains, for a use comprising the above-mentioned use. The invention also relates to the use of isolated Bacillus strains 681,721, A12, 54, 86, 300, 101, 102, 235, and 177, and strains having all of the identifying characteristics of these strains, to prevent or reduce prolapse in an animal.

Abstract: The invention relates to direct-fed microbials for use in E. coli inhibition in animals in combination with enrofloxacin. More particularly, the invention relates to isolated Bacillus strains 9, 57, 71, and 126, and strains having all of the identifying characteristics of these strains, for a use comprising the above-mentioned use.

Abstract: The invention relates to direct-fed microbials for use in E. coli inhibition in animals in combination with antibiotics selected from the group consisting of ceftiofur, oxytetracycline, tulathromycin, and lincomycin. More particularly, the invention relates to isolated Bacillus strains 2, 3, 4, 5, 9, 57, 71, and 126, and strains having all of the identifying characteristics of these strains, for a use comprising the above-mentioned use.

Abstract: The invention relates to direct-fed microbials for use in E. coli and/or Clostridium inhibition in animals in combination with antibiotics. More particularly, the invention relates to isolated Bacillus strains 2, 3, 4, 5, 6, 7, 9, 57, 71, and 126, and strains having all of the identifying characteristics of these strains, for a use comprising the above-mentioned use.

Abstract: The invention relates to direct-fed microbials for use in E. coli inhibition in animals. More particularly, the invention relates to isolated Bacillus strains 101, 235, 77, 177, and 102 and strains having all of the identifying characteristics of these strains, for a use comprising the above-mentioned use. The invention can also be used for treatment of plants and in food processing.

Abstract: The invention relates to compositions comprising microbial strains for use in inhibiting viruses, and methods therefor. More particularly, the invention relates to compositions of isolated Bacillus strains selected from the group consisting of isolated Bacillus strains 300, 86, 101, 235, 102, 177, A12, 54, 681, 721, strains having all of the identifying characteristics of these strains, and combinations thereof, and methods for use of these strains for virus inhibition.

Abstract: The invention relates to direct-fed microbials for use in E. coli inhibition in animals. More particularly, the invention relates to isolated Bacillus strains 101, 235, 77, 177, and 102 and strains having all of the identifying characteristics of these strains, for a use comprising the above-mentioned use. The invention can also be used for treatment of plants and in food processing.

Abstract: The invention relates to direct-fed microbials for use in E. coli, Salmonella, and/or Campylobacter inhibition in animals. More particularly, the invention relates to isolated Bacillus strains A12, 54, 681, 101, 235, and 721, and strains having all of the identifying characteristics of these strains, for a use comprising the above-mentioned use. The invention also relates to the use of isolated Bacillus strains 681,721, A12, 54, 86, 300, 101, 102, 235, and 177, and strains having all of the identifying characteristics of these strains, to prevent or reduce prolapse in an animal.

Abstract: The invention relates to direct-fed microbials for use in E. coli inhibition in animals. More particularly, the invention relates to isolated Bacillus strains 101, 235, 77, 177, and 102 and strains having all of the identifying characteristics of these strains, for a use comprising the above-mentioned use. The invention can also be used for treatment of plants and in food processing.

Abstract: The invention relates to direct-fed microbials for use in E. coli inhibition in animals. More particularly, the invention relates to isolated Bacillus strains 101, 235, 77, 177, and 102 and strains having all of the identifying characteristics of these strains, for a use comprising the above-mentioned use. The invention can also be used for treatment of plants and in food processing.

Abstract: The invention relates to direct-fed microbials for use in E. coli inhibition in animals. More particularly, the invention relates to isolated Bacillus strains 101, 235, 77, 177, and 102 and strains having all of the identifying characteristics of these strains, for a use comprising the above-mentioned use. The invention can also be used for treatment of plants and in food processing.